Key Details
Price
$85.85Last Dividend
$0.70Annual ROE
7.20%Beta
0.35Events Calendar
Next earnings date:
Feb 18, 2025Recent quarterly earnings:
Nov 19, 2024Recent annual earnings:
May 23, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Sept 27, 2024Next split:
N/ARecent split:
Sept 27, 1999Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Last week, Medtronic (NYSE: MDT) announced its financial results for the second quarter of fiscal 2025, which ends in April. The company achieved revenues of $8.4 billion and adjusted earnings of $1.26 per share, surpassing the expected figures of $8.3 billion and $1.25.
Medtronic has received approval from the FDA for its InPen app, which will assist in the introduction of the company's Smart MDI system.
Medtronic's stock price on the NYSE (MDT) has dropped considerably since its high in 2021, creating a chance for investors to find good value. This decline is mainly due to the market adjusting after COVID and challenges that are causing slow growth, but these issues are not expected to persist indefinitely.
The new Smart MDI system will be the first to provide real-time, personalized information on when and how much to dose, even for missed or incorrect mealtime doses. Medtronic plc, a leader in healthcare technology, announced that the U.S. Food and Drug Administration (FDA) has approved its InPen™ app, which includes missed meal dose detection. This approval paves the way for the launch of the Smart MDI system alongside the Simplera™ continuous glucose monitor (CGM).
Medtronic plc announced its Q2 earnings today, showing revenues of $8.4 billion, which is a 5% increase compared to last year, and an adjusted EPS of $1.26, along with a dividend yield of 3.2%. Although the company has experienced steady revenue growth and introduced new products, its share price has not changed much due to variable net income and limited innovation. CEO Geoff Martha pointed out the company's strong performance in areas like diabetes and hypertension but did not give specific long-term growth predictions, leaving market feelings somewhat neutral.
U.S. stocks showed mixed results as trading came to a close, with the Nasdaq Composite rising by about 1% on Tuesday.
Medtronic plc (NYSE:MDT) will hold its Q2 2025 Earnings Conference Call on November 19, 2024, at 8:00 AM ET. Key company participants include CEO Geoff Martha and several executive vice presidents overseeing different divisions. Ryan Weispfenning, the Vice President of Investor Relations, will lead the call and welcomes everyone to the Fiscal '25 Second Quarter Video Earnings Webcast.
Medtronic plc has shared its financial results for the second quarter of fiscal year 2025, which ended on October 25, 2024. The company reported a revenue of $8.4 billion, showing a 5.3% increase overall and a 5.0% rise on an organic basis. Additionally, Medtronic has raised its guidance for organic revenue growth and earnings per share for the fiscal year.
On the most recent trading day, Medtronic (MDT) closed at $87.53, which is an increase of 1.78% compared to its last closing price.
A surgeon from Beverly Hills is taking legal action against Medtronic, alleging that they have infringed on her patent for a hernia repair mesh product. This lawsuit is part of a growing number of patent disputes involving Medtronic.
FAQ
- What is the primary business of Medtronic?
- What is the ticker symbol for Medtronic?
- Does Medtronic pay dividends?
- What sector is Medtronic in?
- What industry is Medtronic in?
- What country is Medtronic based in?
- When did Medtronic go public?
- Is Medtronic in the S&P 500?
- Is Medtronic in the NASDAQ 100?
- Is Medtronic in the Dow Jones?
- When was Medtronic's last earnings report?
- When does Medtronic report earnings?
- Should I buy Medtronic stock now?